MA52617A - Biomarqueurs sanguins de l'accident vasculaire cérébral - Google Patents

Biomarqueurs sanguins de l'accident vasculaire cérébral

Info

Publication number
MA52617A
MA52617A MA052617A MA52617A MA52617A MA 52617 A MA52617 A MA 52617A MA 052617 A MA052617 A MA 052617A MA 52617 A MA52617 A MA 52617A MA 52617 A MA52617 A MA 52617A
Authority
MA
Morocco
Prior art keywords
cerebral vascular
blood biomarkers
vascular accident
accident
biomarkers
Prior art date
Application number
MA052617A
Other languages
English (en)
Inventor
Emmanuelle Genin
Serge Timsit
Original Assignee
Centre Hospitalier Regional Et Univ De Brest
Francais Du Sang Ets
Inst Nat Sante Rech Med
Univ Bretagne Occidentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional Et Univ De Brest, Francais Du Sang Ets, Inst Nat Sante Rech Med, Univ Bretagne Occidentale filed Critical Centre Hospitalier Regional Et Univ De Brest
Publication of MA52617A publication Critical patent/MA52617A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA052617A 2018-05-16 2019-05-16 Biomarqueurs sanguins de l'accident vasculaire cérébral MA52617A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18305600 2018-05-16

Publications (1)

Publication Number Publication Date
MA52617A true MA52617A (fr) 2021-03-24

Family

ID=62386311

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052617A MA52617A (fr) 2018-05-16 2019-05-16 Biomarqueurs sanguins de l'accident vasculaire cérébral

Country Status (13)

Country Link
US (1) US12247257B2 (fr)
EP (1) EP3794355A1 (fr)
JP (2) JP7463351B2 (fr)
KR (1) KR20210049026A (fr)
CN (1) CN112424609A (fr)
AU (1) AU2019270404B2 (fr)
BR (1) BR112020023259A2 (fr)
CA (1) CA3100171A1 (fr)
IL (1) IL278666B2 (fr)
MA (1) MA52617A (fr)
MX (1) MX2020012297A (fr)
SG (1) SG11202011369VA (fr)
WO (1) WO2019219831A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220093267A1 (en) * 2019-01-22 2022-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Noninvasive real-time patient-specific assessment of stroke severity
CN114107487B (zh) * 2021-12-23 2024-01-09 太原市精神病医院 一种可用于诊断脑卒中的产品
CN116705296B (zh) * 2023-06-06 2024-09-13 中国科学院深圳先进技术研究院 一种基于常规mri序列对gbm患者进行风险分层的方法及系统
WO2025151599A1 (fr) * 2024-01-09 2025-07-17 Morehouse School Of Medicine Procédé à base d'arn pour l'évaluation et le traitement d'accident vasculaire cérébral

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO2003008647A2 (fr) * 2000-11-28 2003-01-30 University Of Cincinnati Evaluation sanguine de maux
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
WO2013103781A1 (fr) 2012-01-07 2013-07-11 The Regents Of The University Of California Biomarqueurs permettant de diagnostiquer l'ischémie.
WO2014052461A1 (fr) * 2012-09-25 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Traitement d'une lésion du système nerveux central (snc)
CN105026579A (zh) 2013-02-01 2015-11-04 西弗吉尼亚大学 用于测定中风症状发作的时间的生物标志物算法以及方法
US11021750B2 (en) 2013-10-13 2021-06-01 The Research Foundation For State University Of Newyork Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
CA2992139A1 (fr) * 2015-07-10 2017-01-19 West Virginia University Marqueurs d'accident vasculaire cerebral et de gravite d'accident vasculaire cerebral
EP3520115A4 (fr) 2016-10-03 2020-09-16 West Virginia University Recherche mise en oeuvre par ordinateur de biomarqueurs de l'interruption de la barrière hémato-encéphalique

Also Published As

Publication number Publication date
JP7463351B2 (ja) 2024-04-08
EP3794355A1 (fr) 2021-03-24
IL278666B1 (en) 2025-02-01
IL278666A (en) 2020-12-31
AU2019270404A2 (en) 2020-12-17
BR112020023259A2 (pt) 2021-02-23
US20210214793A1 (en) 2021-07-15
MX2020012297A (es) 2021-03-25
IL278666B2 (en) 2025-06-01
AU2019270404A1 (en) 2020-12-10
KR20210049026A (ko) 2021-05-04
JP2021523744A (ja) 2021-09-09
AU2019270404B2 (en) 2025-04-17
WO2019219831A1 (fr) 2019-11-21
US12247257B2 (en) 2025-03-11
CA3100171A1 (fr) 2019-11-21
SG11202011369VA (en) 2020-12-30
CN112424609A (zh) 2021-02-26
JP2024075761A (ja) 2024-06-04

Similar Documents

Publication Publication Date Title
EP3442612A4 (fr) Cathéters à ballonnet revêtus de médicament pour lumières corporelles
EP4000540C0 (fr) Cathéter de récupération de caillot actionné
EP3917590C0 (fr) Cathéter vasculaire
MA52665A (fr) Procédé d'amélioration de l'expression de l'hémoglobine foetale
EP3471660A4 (fr) Dispositif médical pour le traitement de malformations vasculaires
IL288590A (en) Automatic prediction of blood infections
EP3482201A4 (fr) Diagnostic précoce d'infections
IL288500A (en) Clot retrieval
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
IL280991A (en) Platelet count-agnostic methods of treating myelofibrosis
EP3735209A4 (fr) Traitement de la progression de la myopie
EP3936251A4 (fr) Structure de carrosserie de voiture
EP3803394A4 (fr) Biomarqueurs circulatoires pour la santé placentaire ou foetale
EP3632431A4 (fr) Agent de prévention ou de traitement de l'atrophie cérébrale
HUE062715T2 (hu) Eljárások perszonalizált véredények elõállítására
EP3471685A4 (fr) Flacons à usage unique pour l'administration de gouttes ophtalmiques
EP3551666A4 (fr) Variants d'anticorps franchissant la barrière hémato-encéphalique et leurs utilisations
EP3641846A4 (fr) Hémofiltre pour la filtration in vivo du sang
EP4415796A4 (fr) Cathéter d'angiographie cérébrale amélioré
IL270927B (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
EP3912890A4 (fr) Structure de carrosserie de voiture
SI3794148T1 (sl) Postopki za diagnostiko anevrizme ali raka
EP3675715A4 (fr) Stratégies de détection pour l'évaluation de la santé de prothèses ostéo-intégrées
EP3883972A4 (fr) Polypeptide pour le traitement de caillots sanguins pathologiques
EP3244893A4 (fr) Bloqueurs de canaux sodiques pour le traitement de troubles de la peau